Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Core Viewpoint - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, with a specific emphasis on overcoming limitations of existing treatments for kinase targets [3]. Group 1: Company Overview - Nuvalent, Inc. is listed on Nasdaq under the ticker NUVL and specializes in creating precisely targeted therapies for cancer patients [3]. - The company leverages expertise in chemistry and structure-based drug design to develop innovative small molecules aimed at overcoming resistance and minimizing adverse events [3]. - Nuvalent is advancing a robust pipeline that includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [3]. Group 2: Upcoming Events - James Porter, Ph.D., CEO, and Alexandra Balcom, CFO, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on April 8, 2025, at 2:30 p.m. ET [1]. - A live webcast of the event will be available on the company's website and archived for 30 days post-presentation [2].